Publications

1 - 10 of 24 results

Search term:

How to recognize inborn errors of immunity in a child presenting with a lymphoid malignancy: Guidelines for the pediatric haemato-oncologist. Vrije Universiteit Brussel

Jutte Van Der Werff Ten Bosch, Eva Hlavackova, Tim Lammens, Ute Fischer, Francesco Saettini, Sujal Gosh, Roula Farah, Delphine Bogaert, Chris M Bacon, Simon Bomken, et al.
Inborn errors of immunity (IEI) are a group of disorders caused by genetically determined defects in the immune system, leading to infections, autoimmunity, autoinflammation and an increased risk of malignancy. In some cases, a malignancy might be the first sign of an underlying IEI. As therapeutic strategies might be different in these patients, recognition of the underlying IEI by the pediatric hemato-oncologist is important. This article, ...

Deciphering the Non-Coding RNA Landscape of Pediatric Acute Myeloid Leukemia Vrije Universiteit Brussel KU Leuven

Jolien Vanhooren, Laurens Van Camp, Barbara Depreter, Martijn de Jong, Anne Uyttebroeck, An Van Damme, Laurence Dedeken, Marie-Françoise Dresse, Jutte Van Der Werff Ten Bosch, Mattias Hofmans, et al.

Pediatric acute myeloid leukemia (pedAML) is a heterogeneous blood cancer that affects children. Although survival rates have significantly improved over the past few decades, 20-30% of children will succumb due to treatment-related toxicity or relapse. The molecular characterization of the leukemic stem cell, shown to be responsible for relapse, is needed to improve treatment options and survival. Recently, it has become clear that ...

Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course Vrije Universiteit Brussel

Fanny Delehaye, Jérémie Rouger, David Brossier, Meinolf Suttorp, Adalet Meral Güneş, Birgitta Versluys, Chi-Kong Li, Krzysztof Kalwak, Birgitte Lausen

The clinical presentation of chronic myeloid leukemia (CML) at diagnosis differs in children compared to adults. At younger age, anemia appears to be frequent at diagnosis, but its prevalence and its impact on prognosis are not well known. In the International Registry of Childhood CML, we selected children and adolescents in chronic phase at diagnosis of CML and treated upfront with imatinib. We examined their hemoglobin level at diagnosis ...

The role of TARP as an antigen in cancer immunotherapy. Vrije Universiteit Brussel

Jolien Vanhooren, Charlotte Derpoorter, Barbara Depreter, larissa deneweth, J. Philippe, Barbara De Moerloose, Tim Lammens

In recent decades, immunotherapy has become a pivotal element in cancer treatment. A remaining challenge is the identification of cancer-associated antigens suitable as targets for immunotherapeutics with potent on-target and few off-tumor effects. The T-cell receptor gamma (TCRγ) chain alternate reading frame protein (TARP) was first discovered in the human prostate and androgen-sensitive prostate cancer. Thereafter, TARP was also identified ...

Long Non-Coding RNAs as Novel Therapeutic Targets in Juvenile Myelomonocytic Leukemia. I Vrije Universiteit Brussel Ghent University

Mattias Hofmans, Tim Lammens, Barbara Depreter

Juvenile myelomonocytic leukemia (JMML) treatment primarily relies on hematopoietic stem cell transplantation and results in long-term overall survival of 50–60%, demonstrating a need to develop novel treatments. Dysregulation of the non-coding RNA transcriptome has been demonstrated before in this rare and unique disorder of early childhood. In this study, we investigated the therapeutic potential of targeting overexpressed long non-coding ...

Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL) Vrije Universiteit Brussel Ghent University KU Leuven

Mattias Hofmans, Pieter Van Vlierberghe, Nicolas Sirvent, Vitor Costa, Anne Uyttebroeck

Outcomes in childhood T-cell acute lymphoblastic leukaemia (T-ALL) are steadily improving due to intensive therapy. Between 1989 and 2008, 599 children with newly diagnosed T-ALL were enrolled in two successive European Organization for Research and Treatment of Cancer - Children's Leukaemia Group trials (58881 and 58951), both based on the Berlin-Frankfurt-Munster protocol and without cranial irradiation. In the latter trial induction ...